Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease

Chahine, Lana M.; Daley, Joseph T.; Horn, Stacy; Duda, John E.; Colcher, Amy; Hurtig, Howard I.; Cantor, Charles R.; Dahodwala, Nabila

doi:10.1016/j.parkreldis.2013.05.009

Cited by 44 publications

(25 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 In patients with more advanced disease, tremor, rigidity, pain, and impaired bed mobility contribute to difficulty in sleeping, and PD medications can adversely affect sleep as well. 3, 14 Neuropsychiatric symptoms may also account for sleep problems in some PD patients. Thus, PD sleep problems are likely multifactorial.…”

Section: Discussionmentioning

confidence: 99%

Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series

Humbert

Findley

Hernandez-Con

et al. 2017

npj Parkinson's Disease

View full text Add to dashboard Cite

Chronic insomnia is common in patients with Parkinson’s disease. There are limited data to guide its treatment in this patient population, especially in regards to non-pharmacologic interventions, some of which are highly effective in the non-Parkinson’s disease population. The aim of this study is to describe a series of Parkinson’s disease patients who underwent cognitive behavioral therapy for insomnia (CBTi). Parkinson’s disease patients who had undergone a baseline and at least one follow-up CBTi session were identified. Electronic medical records and pre-treatment and post-treatment patient sleep diaries were reviewed. Sleep measures of interest included wake time after sleep onset, sleep efficiency, sleep onset latency, and total sleep time. Pre-treatment and post-treatment values were compared within subjects using paired t-test. Five patients were included. Patients attended an average of eight sessions of CBTi (range 5–12). Significant increases in sleep efficiency (p = 0.02) and decreases in number of awakenings per night (p = 0.02) were found. Our data provide preliminary evidence that cognitive behavioral therapy is an effective treatment for insomnia in Parkinson’s disease, and is well tolerated and well received by patients. Given the limited data supporting use of medications to treat chronic insomnia in Parkinson’s disease, combined with their risks, randomized trials to demonstrate the efficacy of CBTi in Parkinson’s disease are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series

Humbert

Findley

Hernandez-Con

et al. 2017

npj Parkinson's Disease

View full text Add to dashboard Cite

show abstract

“…Its effects on sleep are influenced by the dose and activation of specific dopaminergic receptors. Low doses of dopaminergic medications act on pre-synaptic D2 receptors, facilitating sleep and reducing wakefulness (9, 12, 13). In contrast, higher doses of dopaminergic medication act at post-synaptic D1 and D2 receptors, inhibiting sleep and increasing insomnia (9, 10, 14).…”

Section: Introductionmentioning

confidence: 99%

Sleep and Circadian Rhythm Disorders in Parkinson’s Disease

Gros

Videnović

2017

Curr Sleep Medicine Rep

View full text Add to dashboard Cite

Purpose of review Sleep disorders are among the most challenging non-motor features of Parkinson’s disease (PD) and significantly affect quality of life. Research in this field has gained recent interest among clinicians and scientists and is rapidly evolving. This review is dedicated to sleep and circadian dysfunction associated with PD. Recent findings Most primary sleep disorders may co-exist with PD; majority of these disorders have unique features when expressed in the PD population. Summary We discuss the specific considerations related to the common sleep problems in Parkinson’s disease including insomnia, rapid eye movement sleep behavior disorder, restless legs syndrome, sleep disordered breathing, excessive daytime sleepiness and circadian rhythm disorders. Within each of these sleep disorders, we present updated definitions, epidemiology, etiology, diagnosis, clinical implications and management. Furthermore, areas of potential interest for further research are outlined.

show abstract

“…These findings support evidence from other cross-sectional studies investigating insomnia in PD. [117][118][119][120][121][122] One recent longitudinal study among 421 people with PD found that, over an average of 4.6 years, insomnia was more common with longer duration of PD and in women. 123 Further, depressive symptoms and dopamine agonists were risk factors for developing insomnia; motor symptoms and sleep medication use were associated with more severe insomnia.…”

Section: Parkinson's Disease and Related Conditionsmentioning

confidence: 99%

Sleep Disturbance, Cognitive Decline, and Dementia: A Review

Wennberg

Wu²,

Rosenberg³

et al. 2017

Semin Neurol

200

View full text Add to dashboard Cite

Approximately half of older people report sleep disturbances, which are associated with various health conditions, including neurodegenerative disease and dementia. Indeed, 60 to 70% of people with cognitive impairment or dementia have sleep disturbances, which are linked to poorer disease prognosis. Sleep disturbances in people with dementia have long been recognized and studied; however, in the past 10 years, researchers have begun to study disturbed sleep, including sleep fragmentation, abnormal sleep duration, and sleep disorders, as risk factors for dementia. In this review the authors summarize evidence linking sleep disturbance and dementia. They describe how specific aspects of sleep (e.g., quality, duration) and the prevalence of clinical sleep disorders (e.g., sleep-disordered breathing, rapid eye movement sleep behavior disorder) change with age; how sleep parameters and sleep disorders are associated with the risk of dementia; how sleep can be disturbed in dementia; and how disturbed sleep affects dementia prognosis. These findings highlight the potential importance of identifying and treating sleep problems and disorders in middle-aged and older adults as a strategy to prevent cognitive decline and dementia. The authors also review recent evidence linking sleep disturbances to the pathophysiology underlying dementing conditions, and briefly summarize available treatments for sleep disorders in people with dementia.

show abstract

Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease

Cited by 44 publications

References 34 publications

Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series

Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series

Sleep and Circadian Rhythm Disorders in Parkinson’s Disease

Sleep Disturbance, Cognitive Decline, and Dementia: A Review

Contact Info

Product

Resources

About